The Saudi Food and Drug Authority (SFDA) has granted conditional approval for Anktiva, a groundbreaking cancer therapy, for ...

People who are colorblind may be missing a life-saving warning sign of bladder cancer. Analysis of the electronic health ...

The Saudi Food and Drug Authority (SFDA) has granted conditional approval for Anktiva (nogapendekin alfa inbakicept) in ...

Saudi Arabia's Food and Drug Authority grants conditional approval for Anktiva, a new cancer therapy for advanced lung and ...

Saudi Arabia leads the way as the first country to grant conditional approval for Anktiva, a groundbreaking treatment for ...

Cancer survival in the U.S. has climbed to 70%, reflecting major advances in treatment, early detection and personalized care ...

The American Cancer Society’s 2026 Cancer Statistics report shows the five-year survival rate for all cancers has reached a ...

ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...

A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder ...

Researchers found better detection, treatment and decreased smoking have been immensely helpful in reducing deaths due to ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.

By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.